TY - JOUR
AU - 
AB - This is a case report describing an 83-year-old male with suspected immune checkpoint inhibitor mediated myocarditis after two cycles of ipilimumab and nivolumab. The patient was treated with intravenous (IV) steroids after other common causes of his symptoms were ruled out. While the patient’s lab values reflected a slight treatment response, ultimately the patient expired due to progression of symptoms. Myocarditis due to immune checkpoint inhibitor therapy is a rare but fatal occurrence, and more data is needed to determine the optimal treatment and dosing strategy. Keywords: cardiology; oncology; immune checkpoint inhibitors; myocarditis Introduction be seen in a heart transplant experiencing acute rejection [5]. Troponin and brain-type natriuretic peptide (BNP) are measured to predict Immune checkpoint inhibitors are antineoplastic medications prescribed prognosis and guide treatment decisions. It is important to recognize and for the treatment of various malignancies, including breast, bladder, diagnosis this condition quickly in order to begin treatment and improve cervical, colon, head and neck, Hodgkin lymphoma, liver, lung, renal, patient outcomes [4]. skin, stomach, and rectal cancers. Most commonly prescribed medications within this class include ipilimumab and nivolumab, Case Report however there are several other agents available, including avelumab, This patient was an 83-year-old male who 
TI - Immune Checkpoint Inhibitor Mediated Myocarditis: A Case Report
JF - Clinical Cardiology and Cardiovascular Interventions
DO - 10.31579/2641-0419/275
DA - 2022-10-19
UR - https://www.deepdyve.com/lp/unpaywall/immune-checkpoint-inhibitor-mediated-myocarditis-a-case-report-bxU0gaGh4L
DP - DeepDyve
ER -